1
|
Camu W, De La Cruz E, Esselin F. Therapeutic tools for familial ALS. Rev Neurol (Paris) 2023; 179:49-53. [PMID: 36503675 DOI: 10.1016/j.neurol.2022.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 10/20/2022] [Accepted: 10/21/2022] [Indexed: 12/13/2022]
Abstract
Familial ALS (FALS) accounts for 10 to 15% of ALS cases. In more than 70% of FALS patients, a causal gene is identified and animal models have been developed for a subset of them, mainly for the most frequently mutated genes. Therapeutic tools to treat those patients are dominated by gene-specific therapy and the most advanced approaches target the SOD1 gene mutations. Either by direct delivery of antisense oligonucleotides (ASO) or using viral vectors such as adenoviruses (AAV) to deliver ASOs, gene specific therapies have shown promising results in animal models. The recent use of subpial injections of AAV9+anti SOD1 ASO now shows that the disease is completely prevented or stopped in the animal, depending on the moment of injection, e.g., before or after disease onset. However, the use of viral vectors in humans seems to be limited at least by their immunogenicity. Antibody-based therapies are also efficient to treat animal models, but to a lesser extent. Most of the experiments targeted the SOD1 protein in its misfolded conformation. This approach seems better tolerated than the AAV one, an important limit being the choice of the epitope. Unexpectedly, some advances in treating the C9ORF72 animal model have been obtained using a modulation of microbiota, and this strategy has the great advantage to have an easy route of administration and a good safety profile. The landscape of experimental FALS treatment is rapidly evolving and results are promising. This is an important unmet need for ALS patients and several human phase I, II and III trials are ongoing.
Collapse
Affiliation(s)
- W Camu
- Explorations neurologiques et centre de référence SLA, université de Montpellier, CHU Gui de Chauliac, INM, Inserm, Montpellier, France.
| | - E De La Cruz
- Explorations neurologiques et centre de référence SLA, université de Montpellier, CHU Gui de Chauliac, INM, Inserm, Montpellier, France
| | - F Esselin
- Explorations neurologiques et centre de référence SLA, université de Montpellier, CHU Gui de Chauliac, INM, Inserm, Montpellier, France
| |
Collapse
|
2
|
Lagrange E, Vernoux JP, Reis J, Palmer V, Camu W, Spencer PS. An amyotrophic lateral sclerosis hot spot in the French Alps associated with genotoxic fungi. J Neurol Sci 2021; 427:117558. [PMID: 34216974 DOI: 10.1016/j.jns.2021.117558] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 05/31/2021] [Accepted: 06/22/2021] [Indexed: 12/11/2022]
Abstract
Between 1990 and 2018, 14 cases of amyotrophic lateral sclerosis (ALS) were diagnosed in residents of, and in visitors with second homes to, a mountainous hamlet in the French Alps. Systematic investigation revealed a socio-professional network that connected ALS cases. Genetic risk factors for ALS were excluded. Several known environmental factors were scrutinized and eliminated, notably lead and other chemical contaminants in soil, water or home-grown vegetation used for food, radon and electromagnetic fields. Some lifestyle-related behavioral risk factors were identified: Prior to clinical onset of motor neuron disease, some patients had a high degree of athleticism and smoked tobacco. Recent investigations on site, based on a new hypothesis, showed that all patients had ingested wild mushrooms, notably poisonous False Morels. Half of the ALS cohort reported acute illness following Gyromitra gigas mushroom consumption. This finding supports the hypothesis that genotoxins of fungal origin may induce motor neuron degeneration.
Collapse
Affiliation(s)
- E Lagrange
- Department of Neurology, Reference Center of Neuromuscular Disease and ALS consultations, Grenoble University Hospital, 38000 Grenoble, France
| | - J P Vernoux
- Normandie Univ, UNICAEN, ABTE, 14000 Caen, France
| | - J Reis
- Department of Neurology, University of Strasbourg, University Hospital of Strasbourg, Strasbourg, France; Association RISE, 3, rue du Loir, 67205 Oberhausbergen, France
| | - V Palmer
- Department of Neurology, School of Medicine, Oregon Health and Science University, Portland, OR 97201, USA
| | - W Camu
- ALS Reference Center, Montpellier University Hospital and University of Montpellier, Inserm UMR1051, 34000 Montpellier, France
| | - P S Spencer
- Department of Neurology, School of Medicine, Oregon Health and Science University, Portland, OR 97201, USA; Oregon Institute of Occupational Health Sciences, Oregon Health and Science University, Portland, OR 97201, USA.
| |
Collapse
|
3
|
Marelli C, Badiou S, Genestet S, Larrieu L, Damier P, Camu W, Planes M, Koenig M, Guissart C. Autosomal dominant SPG9: intrafamilial variability and onset during pregnancy. Neurol Sci 2020; 41:1931-1933. [PMID: 32221810 DOI: 10.1007/s10072-020-04341-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2019] [Accepted: 03/13/2020] [Indexed: 10/24/2022]
Abstract
INTRODUCTION The ALDH18A1 gene, encoding delta-1-pyrroline-5-carboxylate synthase (P5CS), is responsible for an autosomal recessive disease with severe developmental delay; more recently, ALDH18A1 was found to be responsible for SPG9, an autosomal dominant (AD) spastic paraplegia. CASE REPORT We report a three-generation family with AD SPG9, initially suspected because of low citrulline on fasting plasma amino acid chromatography (AAC). Interestingly, in two patients, the spastic paraplegia appeared during pregnancy. One subject presented a severe childhood-onset form while another subject had a mild late-onset disease. CONCLUSION The description of this family is of particular interest: it highlights the possibility of transient or permanent aggravation of spastic paraplegia due to SPG9 during pregnancy, suggesting a direct link between neurological symptoms and amino acid defect in a period of higher requirements and the potential benefit of amino acid supplementation; it underscores the value of plasma citrulline on fasting plasma AAC as a biomarker for this disease; it shows the variable expression of the disease.
Collapse
Affiliation(s)
- C Marelli
- Department of Neurology, Expert Centre for Neurogenetic Diseases and Adult Mitochondrial and Metabolic Diseases, Gui de Chauliac University Hospital Montpellier, 80, Avenue A Fliche, 34295, Montpellier, France. .,Laboratoire de Génétique de Maladies Rares EA7402, Institut Universitaire de Recherche Clinique, Université de Montpellier, Montpellier, France. .,Inserm U1198 MMDN, Montpellier, France.
| | - S Badiou
- Biochemistry Laboratory, Lapeyronie Hospital, Montpellier, France.,PhyMedExp, INSERM, CNRS, CHU de Montpellier, Université de Montpellier, Montpellier, France
| | - S Genestet
- Hôpital de la Cavale Blanche, Service d'Explorations Fonctionnelles Neurologiques, CHRU de Brest, 29609, Brest, France
| | - L Larrieu
- Institut Universitaire de Recherche Clinique, Laboratoire de Génétique de Maladies Rares EA7402, Laboratoire de Génétique Moléculaire, University Hospital, Université de Montpellier, Montpellier, France
| | - P Damier
- Service de Neurologie, CHU de Nantes, Nantes, France
| | - W Camu
- Expert Center for Motor Neuron Diseases, Explorations Neurologiques, CHU and Université de Montpellier, Montpellier, France
| | - M Planes
- Service de Genetique Clinique, CHRU Morvan, 29609, Brest, France
| | - M Koenig
- Institut Universitaire de Recherche Clinique, Laboratoire de Génétique de Maladies Rares EA7402, Laboratoire de Génétique Moléculaire, University Hospital, Université de Montpellier, Montpellier, France
| | - C Guissart
- Institut Universitaire de Recherche Clinique, Laboratoire de Génétique de Maladies Rares EA7402, Laboratoire de Génétique Moléculaire, University Hospital, Université de Montpellier, Montpellier, France
| |
Collapse
|
4
|
Corcia P, Lumbroso S, Cazeneuve C, Mouzat K, Camu W, Vourc'h P. Pre-symptomatic diagnosis in ALS. Rev Neurol (Paris) 2020; 176:166-169. [PMID: 31932031 DOI: 10.1016/j.neurol.2019.07.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2019] [Revised: 07/10/2019] [Accepted: 07/16/2019] [Indexed: 12/11/2022]
Abstract
Pathophysiology of amyotrophic lateral sclerosis (ALS) remains partially understood even though it is accepted worldwide that motor neuron death results from a pluri-factorial process with a variable role of genetic factors. Although not distinguishable from a clinical point of view, familial forms of ALS (fALS, 10% of cases) and sporadic forms (sALS, 90% of cases) can be described. Since the identification of superoxide dismutase 1 gene (SOD1) mutations, more than 30 genes have been linked to fALS. Among these genes, five (C9ORF72, SOD1, TARDBP, FUS, TBK1) seem predominant with mutation frequencies of 40%, 20%, 5%, <5%, <5% in fALS and 6%, 3%, and <1% for the last three in sALS, respectively. The situation that classically leads to request genetic screening is the presence of a familial history of motor neuron disorders (MND) or fronto-temporal lobar dementia (FTLD). However, this dichotomy between fALS and sALS based on familial history can lead to mistakes since illegitimacy, ignorance of MND, FTD or psychiatric disorders within the family due to a familial censorship or lack of familial relationship, or a recessive autosomal inheritance could wrongly lead to failing to recognize a familial form. The significant development of genetic research and easier access to genetic tests in fALS increase the number of situations for which gene mutations are identified. The consequence is an increase in genetic requests from relatives of ALS patients who are eager to know their own genetic status and their own individual risk to develop ALS. Pre-symptomatic testing is thus becoming a daily issue in ALS Centers. This led us to propose a framework for such pre-symptomatic genetic testing for people at risk for developing ALS.
Collapse
Affiliation(s)
- P Corcia
- Centre Constitutif SLA, CHU Bretonneau, Tours, France; UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.
| | - S Lumbroso
- Motoneuron Disease: Pathophysiology and Therapy, INM, University Montpellier, Montpellier, France; Laboratoire de Biochimie et Biologie Moléculaire, CHU Nîmes, Nîmes, France
| | - C Cazeneuve
- Unité Fonctionnelle de Neurogénétique Moléculaire et Cellulaire, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, France
| | - K Mouzat
- Motoneuron Disease: Pathophysiology and Therapy, INM, University Montpellier, Montpellier, France; Laboratoire de Biochimie et Biologie Moléculaire, CHU Nîmes, Nîmes, France
| | - W Camu
- Centre Consitutif SLA, Hopital Guy de Chauliac, Montpellier, France
| | - P Vourc'h
- Motoneuron Disease: Pathophysiology and Therapy, INM, University Montpellier, Montpellier, France; Laboratoire de Biochimie et Biologie Moléculaire, CHU Nîmes, Nîmes, France; Service de Biochimie et Biologie Moléculaire, CHRU Tours, France
| | | |
Collapse
|
5
|
Spencer P, Lagrange E, Camu W. ALS and environment: Clues from spatial clustering? Rev Neurol (Paris) 2019; 175:652-663. [DOI: 10.1016/j.neurol.2019.04.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Accepted: 04/23/2019] [Indexed: 12/14/2022]
|
6
|
Thouvenot E, Demattei C, Lehmann S, Maceski‐Maleska A, Hirtz C, Juntas‐Morales R, Pageot N, Esselin F, Alphandéry S, Vincent T, Camu W. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol 2019; 27:251-257. [DOI: 10.1111/ene.14063] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Accepted: 08/05/2019] [Indexed: 12/12/2022]
Affiliation(s)
- E. Thouvenot
- Service de Neurologie CHU Nîmes CNRS INSERM Univ Montpellier Nîmes France
| | - C. Demattei
- Département d'Information Médicale CHU Nîmes Univ Montpellier Nîmes France
| | - S. Lehmann
- Laboratoire de Biochimie et Plateforme de Protéomique Clinique CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - A. Maceski‐Maleska
- Laboratoire de Biochimie et Plateforme de Protéomique Clinique CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - C. Hirtz
- Laboratoire de Biochimie et Plateforme de Protéomique Clinique CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - R. Juntas‐Morales
- Centre de référence SLA CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - N. Pageot
- Centre de référence SLA CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - F. Esselin
- Centre de référence SLA CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - S. Alphandéry
- Centre de référence SLA CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - T. Vincent
- Laboratoire d'Immunologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - W. Camu
- Centre de référence SLA CHU Montpellier INSERM Univ Montpellier Montpellier France
| |
Collapse
|
7
|
Moiziard V, Pellegrin A, Palayer C, Cortez C, Jourdan C, Camu W, Morales R, Laffont I. Treatment of post-poliomyelitis syndrome by intravenous immunoglobulin: A retrospective study of clinical criteria. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
8
|
Bousquet J, Bourret R, Camuzat T, Augé P, Bringer J, Noguès M, Jonquet O, de la Coussaye JE, Ankri J, Cesari M, Guérin O, Vellas B, Blain H, Arnavielhe S, Avignon A, Combe B, Canovas G, Daien C, Dray G, Dupeyron A, Jeandel C, Laffont I, Laune D, Marion C, Pastor E, Pélissier JY, Galan B, Reynes J, Reuzeau JC, Bedbrook A, Granier S, Adnet PA, Amouyal M, Alomène B, Bernard PL, Berr C, Caimmi D, Claret PG, Costa DJ, Cristol JP, Fesler P, Hève D, Millot-Keurinck J, Morquin D, Ninot G, Picot MC, Raffort N, Roubille F, Sultan A, Touchon J, Attalin V, Azevedo C, Badin M, Bakhti K, Bardy B, Battesti MP, Bobia X, Boegner C, Boichot S, Bonnin HY, Bouly S, Boubakri C, Bourrain JL, Bourrel G, Bouix V, Bruguière V, Cade S, Camu W, Carre V, Cavalli G, Cayla G, Chiron R, Coignard P, Coroian F, Costa P, Cottalorda J, Coulet B, Coupet AL, Courrouy-Michel MC, Courtet P, Cros V, Cuisinier F, Danko M, Dauenhauer P, Dauzat M, David M, Davy JM, Delignières D, Demoly P, Desplan J, Dujols P, Dupeyron G, Engberink O, Enjalbert M, Fattal C, Fernandes J, Fouletier M, Fraisse P, Gabrion P, Gellerat-Rogier M, Gelis A, Genis C, Giraudeau N, Goucham AY, Gouzi F, Gressard F, Gris JC, Guillot B, Guiraud D, Handweiler V, Hayot M, Hérisson C, Heroum C, Hoa D, Jacquemin S, Jaber S, Jakovenko D, Jorgensen C, Kouyoudjian P, Lamoureux R, Landreau L, Lapierre M, Larrey D, Laurent C, Léglise MS, Lemaitre JM, Le Quellec A, Leclercq F, Lehmann S, Lognos B, Lussert CM, Makinson A, Mandrick K, Mares P, Martin-Gousset P, Matheron A, Mathieu G, Meissonnier M, Mercier G, Messner P, Meunier C, Mondain M, Morales R, Morel J, Mottet D, Nérin P, Nicolas P, Nouvel F, Paccard D, Pandraud G, Pasdelou MP, Pasquié JL, Patte K, Perrey S, Pers YM, Portejoie F, Pujol JLE, Quantin X, Quéré I, Ramdani S, Ribstein J, Rédini-Martinez I, Richard S, Ritchie K, Riso JP, Rivier F, Robine JM, Rolland C, Royère E, Sablot D, Savy JL, Schifano L, Senesse P, Sicard R, Stephan Y, Strubel D, Tallon G, Tanfin M, Tassery H, Tavares I, Torre K, Tribout V, Uziel A, Van de Perre P, Venail F, Vergne-Richard C, Vergotte G, Vian L, Vialla F, Viart F, Villain M, Viollet E, Ychou M, Mercier J. MACVIA-LR (Fighting Chronic Diseases for Active and Healthy Ageing in Languedoc-Roussillon): A Success Story of the European Innovation Partnership on Active and Healthy Ageing. J Frailty Aging 2017; 5:233-241. [PMID: 27883170 DOI: 10.14283/jfa.2016.105] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The Région Languedoc Roussillon is the umbrella organisation for an interconnected and integrated project on active and healthy ageing (AHA). It covers the 3 pillars of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA): (A) Prevention and health promotion, (B) Care and cure, (C) and (D) Active and independent living of elderly people. All sub-activities (poly-pharmacy, falls prevention initiative, prevention of frailty, chronic respiratory diseases, chronic diseases with multimorbidities, chronic infectious diseases, active and independent living and disability) have been included in MACVIA-LR which has a strong political commitment and involves all stakeholders (public, private, patients, policy makers) including CARSAT-LR and the Eurobiomed cluster. It is a Reference Site of the EIP on AHA. The framework of MACVIA-LR has the vision that the prevention and management of chronic diseases is essential for the promotion of AHA and for the reduction of handicap. The main objectives of MACVIA-LR are: (i) to develop innovative solutions for a network of Living labs in order to reduce avoidable hospitalisations and loss of autonomy while improving quality of life, (ii) to disseminate the innovation. The three years of MACVIA-LR activities are reported in this paper.
Collapse
Affiliation(s)
- J Bousquet
- Professor Jean Bousquet, CHRU, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France, Tel +33 611 42 88 47,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Juntas Morales R, Pageot N, Taieb G, Camu W. Adult-onset spinal muscular atrophy: An update. Rev Neurol (Paris) 2017; 173:308-319. [DOI: 10.1016/j.neurol.2017.03.015] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2016] [Revised: 03/01/2017] [Accepted: 03/28/2017] [Indexed: 12/11/2022]
|
10
|
Corcia P, Blasco H, Besson G, Camdessanché JP, Pautot V, Beltran S, Couratier P, Andres C, Camu W, Vourc'h P. SOD1 mutation can mask C9orf72 abnormal expansion. Eur J Neurol 2017; 24:e24. [PMID: 28322003 DOI: 10.1111/ene.13257] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Accepted: 01/11/2017] [Indexed: 12/13/2022]
Affiliation(s)
- P Corcia
- Centre de Ressources et de Compétences SLA, CHU Tours, Tours, France.,Inserm Unit UMR U930, Tours, France.,Fédération des Centres de Ressources et de Compétences de Tours et Limoges, LITORALS, Limoges, France
| | - H Blasco
- Inserm Unit UMR U930, Tours, France
| | - G Besson
- Service de Neurologie, CHU Grenoble, Grenoble, France
| | - J-P Camdessanché
- Centre de Ressources et de Compétences SLA, CHU St Etienne, Saint-Etienne, France
| | - V Pautot
- Centre de Ressources et de Compétences SLA, CHU Angers, Angers, France
| | - S Beltran
- Centre de Ressources et de Compétences SLA, CHU Tours, Tours, France.,Fédération des Centres de Ressources et de Compétences de Tours et Limoges, LITORALS, Limoges, France
| | - P Couratier
- Fédération des Centres de Ressources et de Compétences de Tours et Limoges, LITORALS, Limoges, France.,Centre de Ressources et de Compétences SLA, CHU Limoges, Limoges, France
| | - C Andres
- Inserm Unit UMR U930, Tours, France
| | - W Camu
- Centre de Ressources et de Compétences SLA, CHU Montpellier, Montpellier, France
| | | |
Collapse
|
11
|
Bousquet J, Bourret R, Camuzat T, Augé P, Domy P, Bringer J, Best N, Jonquet O, de la Coussaye JE, Noguès M, Robine JM, Avignon A, Blain H, Combe B, Dray G, Dufour V, Fouletier M, Giraudeau N, Hève D, Jeandel C, Laffont I, Larrey D, Laune D, Laurent C, Mares P, Marion C, Pastor E, Pélissier JY, Radier-Pontal F, Reynes J, Royère E, Ychou M, Bedbrook A, Granier S, Abecassis F, Albert S, Adnet PA, Alomène B, Amouyal M, Arnavielhe S, Asteriou T, Attalin V, Aubas P, Azevedo C, Badin M, Bakhti, Baptista G, Bardy B, Battesti MP, Bénézet O, Bernard PL, Berr C, Berthe J, Bobia X, Bockaert J, Boegner C, Boichot S, Bonnin HY, Boulet P, Bouly S, Boubakri C, Bourdin A, Bourrain JL, Bourrel G, Bouix V, Breuker C, Bruguière V, Burille J, Cade S, Caimmi D, Calmels MV, Camu W, Canovas G, Carre V, Cavalli G, Cayla G, Chiron R, Claret PG, Coignard P, Coroian F, Costa DJ, Costa P, Cottalorda, Coulet B, Coupet AL, Courrouy-Michel MC, Courtet P, Cristol JP, Cros V, Cuisinier F, Daien C, Danko M, Dauenhauer P, Dauzat M, David M, Davy JM, Delignières D, Demoly P, Desplan J, Dhivert-Donnadieu H, Dujols P, Dupeyron A, Dupeyron G, Engberink O, Enjalbert M, Fattal C, Fernandes J, Fesler P, Fraisse P, Froger J, Gabrion P, Galano E, Gellerat-Rogier M, Gellis A, Goucham AY, Gouzi F, Gressard F, Gris JC, Guillot B, Guiraud D, Handweiler V, Hantkié H, Hayot M, Hérisson C, Heroum C, Hoa D, Jacquemin S, Jaber S, Jakovenko D, Jorgensen C, Journot L, Kaczorek M, Kouyoudjian P, Labauge P, Landreau L, Lapierre M, Leblond C, Léglise MS, Lemaitre JM, Le Moing V, Le Quellec A, Leclercq F, Lehmann S, Lognos B, Lussert JM, Makinson A, Mandrick K, Marmelat V, Martin-Gousset P, Matheron A, Mathieu G, Meissonnier M, Mercier G, Messner P, Meunier C, Mondain M, Morales R, Morel J, Morquin D, Mottet D, Nérin P, Nicolas P, Ninot G, Nouvel F, Ortiz JP, Paccard D, Pandraud G, Pasdelou MP, Pasquié JL, Patte K, Perrey S, Pers YM, Picot MC, Pin JP, Pinto N, Porte E, Portejoie F, Pujol JL, Quantin X, Quéré I, Raffort N, Ramdani S, Ribstein J, Rédini-Martinez I, Richard S, Ritchie K, Riso JP, Rivier F, Rolland C, Roubille F, Sablot D, Savy JL, Schifano L, Senesse P, Sicard R, Soua B, Stephan Y, Strubel D, Sultan A, Taddei-Ologeanu, Tallon G, Tanfin M, Tassery H, Tavares I, Torre K, Touchon J, Tribout V, Uziel A, Van de Perre P, Vasquez X, Verdier JM, Vergne-Richard C, Vergotte G, Vian L, Viarouge-Reunier C, Vialla F, Viart F, Villain M, Villiet M, Viollet E, Wojtusciszyn A, Aoustin M, Bourquin C, Mercier J. Introduction. Presse Med 2015; 44 Suppl 1:S1-5. [DOI: 10.1016/j.lpm.2015.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
12
|
Laffont I, Jourdan C, Coroian F, Blain H, Carre V, Viollet E, Tavares I, Fattal C, Gelis A, Nouvel F, Bakhti K, Cros V, Patte K, Schifano L, Porte M, Galano E, Dray G, Fouletier M, Rivier F, Morales R, Labauge P, Camu W, Combe B, Morel J, Froger J, Coulet B, Cottalorda J, Kouyoumdjian P, Jonquet O, Landreau L, Bonnin HY, Hantkié O, Nicolas P, Enjalbert M, Leblond C, Soua B, Coignard P, Guiraud D, Azevedo C, Mottet D, Fraisse P, Pastor E, Mercier J, Bourret R, Bousquet J, Pélissier J, Bardy B, Herisson C, Dupeyron A. [Living Lab MACVIA. Disability]. Presse Med 2015; 44 Suppl 1:S60-9. [PMID: 26482491 DOI: 10.1016/j.lpm.2015.07.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Affiliation(s)
- I Laffont
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France; Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France.
| | - C Jourdan
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France
| | - F Coroian
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France; Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France
| | - H Blain
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France; CHRU de Montpellier, département de gériatrie, 34090 Montpellier, France
| | - V Carre
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France
| | - E Viollet
- CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France; CHU Carémeau, CEDMH, 30029 Nîmes, France
| | - I Tavares
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France
| | - C Fattal
- Association APPROCHE, CMRRF de Kerpape, BP 78, 56275 Ploemeur cedex, France
| | - A Gelis
- Centre Mutualiste Propara, 34000 Montpellier, France
| | - F Nouvel
- CHU Carémeau, CEDMH, 30029 Nîmes, France
| | - K Bakhti
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France; Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France
| | - V Cros
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France
| | - K Patte
- Institut Marin Saint-Pierre, 34250 Palavas les Flots, France
| | - L Schifano
- Institut Marin Saint-Pierre, 34250 Palavas les Flots, France
| | - M Porte
- CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France
| | - E Galano
- CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France
| | - G Dray
- École des Mines d'Alès, 30100 Alès, France
| | | | - F Rivier
- CHU de Montpellier, centre de référence Grand Sud des maladies neuromusculaires, département de neuropédiatrie, 34090 Montpellier, France
| | - R Morales
- CHRU de Montpellier, département de neurologie, 34090 Montpellier, France
| | - P Labauge
- CHRU de Montpellier, département de neurologie, 34090 Montpellier, France
| | - W Camu
- CHRU de Montpellier, département de neurologie, 34090 Montpellier, France
| | - B Combe
- CHRU de Montpellier, département de rhumatologie, 34090 Montpellier, France
| | - J Morel
- CHRU de Montpellier, département de rhumatologie, 34090 Montpellier, France
| | - J Froger
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France; CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France
| | - B Coulet
- CHRU de Montpellier, département de chirurgie orthopédique, 34090 Montpellier, France
| | - J Cottalorda
- CHRU de Montpellier, département de chirurgie orthopédique et plastique infantile, 34090 Montpellier, France
| | - P Kouyoumdjian
- CHU Carémeau, département de chirurgie orthopédique, 30029 Nîmes, France
| | - O Jonquet
- CHRU de Montpellier, département de réanimation, 34090 Montpellier, France
| | - L Landreau
- CHRU de Montpellier, département de réanimation, 34090 Montpellier, France
| | - H-Y Bonnin
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France; CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France
| | - O Hantkié
- Centre Bourgès, groupe Oc Santé, 34173 Castelneau-le-lez cedex, France
| | - P Nicolas
- Centre Bourgès, groupe Oc Santé, 34173 Castelneau-le-lez cedex, France
| | - M Enjalbert
- Centre Bouffard-Vercelli, 66290 Cerbère, France; Association APPROCHE, CMRRF de Kerpape, BP 78, 56275 Ploemeur cedex, France
| | - C Leblond
- Centre Bouffard-Vercelli, 66290 Cerbère, France
| | - B Soua
- Association ADAGES, Les Fontaines d'Ô, 34000 Montpellier, France
| | - P Coignard
- Association APPROCHE, CMRRF de Kerpape, BP 78, 56275 Ploemeur cedex, France
| | - D Guiraud
- Université de Montpellier, laboratoire d'informatique, de robotique et de microélectronique de Montpellier, 34090 Montpellier, France; Institut national de recherche en informatique et en automatique, LIRMM, université de Montpellier, 34090 Montpellier, France
| | - C Azevedo
- Université de Montpellier, laboratoire d'informatique, de robotique et de microélectronique de Montpellier, 34090 Montpellier, France; Institut national de recherche en informatique et en automatique, LIRMM, université de Montpellier, 34090 Montpellier, France
| | - D Mottet
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France
| | - P Fraisse
- Université de Montpellier, laboratoire d'informatique, de robotique et de microélectronique de Montpellier, 34090 Montpellier, France
| | - E Pastor
- CCAS de Lattes, 34970 Lattes, France
| | - J Mercier
- CHRU de Montpellier, U1046 Inserm, université Montpellier 1, 34090 Montpellier, France
| | - R Bourret
- CHRU de Montpellier, Direction générale, 34090 Montpellier, France
| | | | - J Pélissier
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France; CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France
| | - B Bardy
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France
| | - C Herisson
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France; Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France
| | - A Dupeyron
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France; CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France; CHU Carémeau, CEDMH, 30029 Nîmes, France
| |
Collapse
|
13
|
Hinsinger G, Galéotti N, Nabholz N, Urbach S, Rigau V, Demattei C, Lehmann S, Camu W, Labauge P, Castelnovo G, Brassat D, Loussouarn D, Salou M, Laplaud D, Casez O, Bockaert J, Marin P, Thouvenot E. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler 2015; 21:1251-61. [DOI: 10.1177/1352458514561906] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2014] [Accepted: 11/05/2014] [Indexed: 01/15/2023]
Abstract
Background: Despite sensitivity of MRI to diagnose multiple sclerosis (MS), prognostic biomarkers are still needed for optimized treatment. Objective: The objective of this paper is to identify cerebrospinal fluid (CSF) diagnostic biomarkers of MS using quantitative proteomics and to analyze their expression at different disease stages. Methods: We conducted differential analysis of the CSF proteome from control and relapsing–remitting MS (RRMS) patients followed by verification by ELISA of candidate biomarkers in CSF and serum in control, clinically isolated syndrome (CIS), RRMS and progressive MS (PMS) patients. Results: Twenty-two of the 527 quantified proteins exhibited different abundances in control and RRMS CSF. These include chitinase 3-like protein 1 (CHI3L1) and 2 (CHI3L2), which showed a strong expression in brain of MS patients, especially in astrocytes and microglial cells from white matter plaques. CSF and serum CHI3L1 levels increased with the disease stage and CIS patients with high CSF (>189 ng/ml) and serum (>33 ng/ml) CHI3L1 converted more rapidly to RRMS (log rank test, p < 0.05 and p < 0.001, respectively). In contrast, CSF CHI3L2 levels were lower in PMS than in RRMS patients. Accordingly, CSF CHI3L1/CHI3L2 ratio accurately discriminated PMS from RRMS. Conclusions: CSF CHI3L1 and CHI3L2 and serum CHI3L1 might help to define MS disease stage and have a prognostic value in CIS.
Collapse
Affiliation(s)
- G Hinsinger
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - N Galéotti
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - N Nabholz
- Service d’Ophtalmologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - S Urbach
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - V Rigau
- Service d’Anatomopathologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - C Demattei
- Département d’Information Médicale, CHU de Nîmes, France
| | - S Lehmann
- Service de Biochimie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - W Camu
- Service de Neurologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - P Labauge
- Service de Neurologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - G Castelnovo
- Service de Neurologie, Hôpital Carémeau, CHU de Nîmes, France
| | - D Brassat
- Service de Neurologie, Hôpital Purpan, CHU de Toulouse, France
| | - D Loussouarn
- Service d’Anatomopathologie, CHU de Nantes, France
| | | | - D Laplaud
- INSERM 1064, France/Service de Neurologie, CHU de Nantes, France
| | - O Casez
- Service de Neurologie, CHU de Grenoble, France
| | - J Bockaert
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - P Marin
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - E Thouvenot
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France/Service de Neurologie, Hôpital Carémeau, CHU de Nîmes, France
| |
Collapse
|
14
|
Thouvenot E, Orsini M, Daures JP, Camu W. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis. Eur J Neurol 2014; 22:564-9. [DOI: 10.1111/ene.12617] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2014] [Accepted: 10/09/2014] [Indexed: 01/09/2023]
Affiliation(s)
- E. Thouvenot
- Neurology Department; CHRU Caremeau; Nîmes France
- Institut de Génomique Fonctionnelle; UMR5203; Université Montpellier 1 et 2; Montpellier France
| | - M. Orsini
- Laboratory of Biostatistics, Epidemiology and Public Health; University Institute of Clinical Research; Université Montpellier 1; Montpellier France
| | - J.-P. Daures
- Laboratory of Biostatistics, Epidemiology and Public Health; University Institute of Clinical Research; Université Montpellier 1; Montpellier France
| | - W. Camu
- Neurology Department; CHU Gui de Chauliac and INSERM U1051; Université Montpellier 1; Montpellier France
| |
Collapse
|
15
|
Bousquet J, Bourquin C, Augé P, Domy P, Bringer J, Aoustin M, Camuzat T, Bourret R, Best N, Jonquet O, de la Coussaye J, Robine J, Avignon A, Blain H, Giraudeau N, Hève D, Jeandel C, Laffont I, Larrey D, Laurent C, Noguès M, Pélissier J, Radier-Pontal F, Royère E, Bedbrook A, Granier S, Abecassis F, Albert S, Adnet P, Alomène B, Amouyal M, Arnavieilhe S, Attalin V, Aubas P, Badin M, Baptista G, Bardy B, Battesti M, Bénézet O, Bernard P, Berr C, Berthe J, Bockaert J, Boubakri C, Bourdin A, Bourrain J, Bourrel G, Bouix V, Burille J, Cade S, Caimmi D, Calmels M, Camu W, Cavalli G, Cayla G, Chiron R, Combe B, Costa D, Costa P, Courrouy-Michel M, Courtet P, Cristol J, Cuisinier F, Daien C, Danko M, Dauenhauer P, Dauzat M, David M, Davy J, Delignières D, Demoly P, Dhivert-Donnadieu H, Dray G, Dujols P, Dupeyron A, Dupeyron G, Engberink O, Fesler P, Gellerat-Rogier M, Gouzi F, Gressard F, Hoa D, Jacquemin S, Gris J, Guillot B, Handweiler V, Hayot M, Jaber S, Jakovenko D, Jorgensen C, Journot L, Kaczorek M, Lapierre M, Laune D, Léglise M, Le Quellec A, Leclerc F, Lehmann S, Lognos B, Lussert J, Mandrick K, Marmelat V, Martin-Gousset P, Matheron A, Mathieu G, Mercier G, Messner P, Meunier C, Mondain M, Morel J, Morquin D, Nérin P, Ninot G, Nouvel F, Ortiz J, Pandraud G, Pasdelou M, Pasquié J, Pastor E, Perrey S, Pers Y, Picot M, Pin J, Pinto N, Portejoie F, Pujol J, Quantin X, Quéré I, Raffort N, Ramdani S, Reynes J, Ribstein J, Rédini-Martinez I, Richard S, Ritchie K, Rolland C, Roubille F, Roux E, Salvat A, Savy J, Stephan Y, Strubel D, Sultan A, Tallon G, Tassery H, Torre K, Uziel A, Van de Perre P, Vasquez X, Verdier J, Vergotte G, Vian L, Viarouge-Reunier C, Vialla F, Viart F, Villain M, Viollet E, Ankri J, Berrut G, Crooks G, Joël M, Michel J, Samolinski B, Strandberg T, Vellas B, Mercier J. MACVIA-LR, Reference site of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) in Languedoc Roussillon. Eur Geriatr Med 2014. [DOI: 10.1016/j.eurger.2014.07.013] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
16
|
Thouvenot E, Orsini M, Daurès JP, Camu W. Corrélation entre taux de vitamine D et handicap dans la sclérose en plaques. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Outteryck O, Ongagna J, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet J, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol 2013; 21:40-8. [DOI: 10.1111/ene.12204] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2013] [Accepted: 04/30/2013] [Indexed: 11/29/2022]
Affiliation(s)
- O. Outteryck
- Neurologie; Université de Lille Nord de France (EA2686); Hôpital Roger Salengro CHRU Lille; Lille France
| | | | - B. Brochet
- Neurologie; CHU Pellegrin; Bordeaux France
| | - L. Rumbach
- Neurologie; CHU Besançon; Besançon France
| | | | | | - H. Zéphir
- Neurologie; Université de Lille Nord de France (EA2686); Hôpital Roger Salengro CHRU Lille; Lille France
| | | | - E. Berger
- Neurologie; CHU Besançon; Besançon France
| | - M. Cohen
- Neurologie; Hôpital Pasteur; Nice France
| | | | | | | | - P. Cabre
- Neurologie; CHU Fort de France; Fort de France France
| | - J. Pelletier
- Neurologie; Hôpital de la Timone; Marseille France
| | - A. Rico
- Neurologie; Hôpital de la Timone; Marseille France
| | - G. Defer
- Neurologie; CHU Caen; Caen France
| | | | - W. Camu
- Neurologie; CHU Montpellier; Montpellier France
| | | | | | | | | | - P. Labauge
- Neurologie; CHU Montpellier; Montpellier France
| | | | - P. Clavelou
- Neurologie; CHRU Clermont Ferrand; Clermont Ferrand France
| | - O. Casez
- Neurologie; CHU Grenoble; Grenoble France
| | | | - C. Papeix
- Neurologie; Hôpital de la Salpêtrière; Paris France
| | - C. Lubetzki
- Neurologie; Hôpital de la Salpêtrière; Paris France
| | - B. Fontaine
- Neurologie; Hôpital de la Salpêtrière; Paris France
| | - N. Couturier
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | - N. Bohossian
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | - M. Clanet
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | - P. Vermersch
- Neurologie; Université de Lille Nord de France (EA2686); Hôpital Roger Salengro CHRU Lille; Lille France
| | - J. de Sèze
- Neurologie; Hôpital Civil; Strasbourg France
| | - D. Brassat
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | | |
Collapse
|
18
|
Camu W, Tremblier B, Bowerman M, Pageot N, Juntas-Morales R, Scamps F, Raoul C. Neuroinflammation et neuroprotection : exemple de la SLA. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Henderson CE, Bloch-Gallego E, Camu W, Gouin A, Mettling C. Neurotrophic factors in development and plasticity of spinal neurons. Restor Neurol Neurosci 2012; 5:15-28. [PMID: 21551684 DOI: 10.3233/rnn-1993-5105] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Factors affecting neuronal growth may be considered to fall into two major categories: those required for neuronal survival during development or following a lesion, and those which enhance growth or regeneration of axonal or dendritic processes. We briefly review here some recent studies on the former in spinal cord development and plasticity as an introduction to other papers in the session on Factors controlling Neural Growth, and then present in more detail work on factors affecting motoneuron development in vitro. The neurotrophins are a closely-related family of basic neurotrophic factors including nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) and neurotrophins -3, -4 and -5 that enhance neuronal survival by binding to surface receptors whose major components are the trk tyrosine kinases and p75NGF-R. Only the latter has been studied in the context of spinal cord neuroplasticity: its levels on motoneurons are up-regulated following central or peripheral trauma, although its function there remains unknown. Much evidence exists for the existence of 'motoneuron growth factors' involved in regulation of survival and development of spinal motoneurons. Following a critical comparison of techniques for their purification, we review results obtained in vitro and in vivo using known growth factors such as ciliary neurotrophic factor (CNTF), basic fibroblast growth factor (bFGF) and transforming growth factor (TGF/β1). Although none of them satisfies all the criteria for the embryonic 'motoneuron growth factor', CNTF is of potential interest for reducing motoneuron loss in pathological situations.
Collapse
Affiliation(s)
- C E Henderson
- Centre de Recherche de Biochimie Macromoléculaire, UPR 9008 du CNRS/U249 de l'INSERM, B.P. 5051, 34033 Monlpellier CEDEX, (France)
| | | | | | | | | |
Collapse
|
20
|
Le Ber I, Camuzat A, Guillot-Noel L, Guedj E, Hannequin D, Wargon I, Couratier P, Deramecourt V, Berger E, Viennet G, Pasquier F, Lacomblez Aurousseau L, Salachas F, Martinaud O, Golfier V, Puel M, Vercelletto M, Didic M, Sauvee M, Sellal F, Thomas-Anterion C, Campion D, Michel B, Dubois B, Camu W, Seilhean D, Meininger V, Habert MO, Duyckaerts C, Brice A. Frequency and Phenotypes Associated with C9ORF72 Repeat Expansion in French FTLD and FTLD-ALS Patients (S54.003). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.s54.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
21
|
Corcia P, Valdmanis P, Millecamps S, Lionnet C, Blasco H, Mouzat K, Daoud H, Belzil V, Morales R, Pageot N, Danel-Brunaud V, Vandenberghe N, Pradat PF, Couratier P, Salachas F, Lumbroso S, Rouleau GA, Meininger V, Camu W. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology 2012; 78:1519-26. [DOI: 10.1212/wnl.0b013e3182553c88] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
22
|
Corcia P, Petiot P, Stevic Z, Vourc'h P, Morales R, Gordon PH, Pageot N, Andres C, Camu W. Respiratory onset in an ALS family with L144F SOD1 mutation. J Neurol Neurosurg Psychiatry 2011; 82:747-9. [PMID: 20562451 DOI: 10.1136/jnnp.2009.197558] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Familial amyotrophic lateral sclerosis (FALS) cases linked to SOD1 mutations may sometimes present with unusual clinical features such as pure lower motor neuron involvement or sensory signs. The authors describe a FALS pedigree with the L144F SOD1 mutation in which all cases had respiratory involvement as a first symptom. Although atypical clinical features are not rare in ALS families, this is the first pedigree with respiratory-onset in three affected members. This unusual presentation led to delayed diagnosis in the proband and highlights the fact that respiratory-onset can occur in familial ALS cases carrying SOD1 mutation.
Collapse
Affiliation(s)
- P Corcia
- Centre SLA, Service de Neurologie, CHU Bretonneau, Tours, France
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Thouvenot E, Schmidt C, Heroum C, Carlander B, Bonafe A, Camu W. Diabetes insipidus as a first manifestation in multiple sclerosis. Neurology 2011; 76:1939-40. [DOI: 10.1212/wnl.0b013e31821d750c] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
24
|
Carra-Dallière C, Mania A, Carlander B, Camu W, Juntas-Morales R. [Demyelinating disease affecting both central and peripheral nervous system]. Rev Neurol (Paris) 2011; 167:921-5. [PMID: 21596409 DOI: 10.1016/j.neurol.2010.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2010] [Revised: 11/22/2010] [Accepted: 12/23/2010] [Indexed: 01/21/2023]
Abstract
INTRODUCTION Demyelinating disease affecting both the central and the peripheral nervous systems has rarely been reported. CASE REPORT A 30-year-old man, presented with ataxia and diffuse areflexia due to polyneuropathy fullfilling demyelination criteria. His medical history was notable for central nervous system demyelination compatible with multiple sclerosis. He improved transiently with intravenous immunoglobulin and then stabilized with methotrexate. CONCLUSION This case report distinguishes a new kind of inflammatory disease affecting both central and peripheral nervous system. It seems to be different from multiple sclerosis and chronic immune demyelinating polyneuropathy, because of high hyperproteinorachia and absence of oligoclonal bands in the cerebrospinal fluid.
Collapse
Affiliation(s)
- C Carra-Dallière
- Service de neurologie, CHU de Montpellier, hôpital Gui de Chauliac, 80, avenue Augustin-Flîche, 34295 Montpellier cedex 5, France
| | | | | | | | | |
Collapse
|
25
|
Praline J, Blasco H, Vourc'h P, Garrigue MA, Gordon PH, Camu W, Corcia P, Andres CR. APOE ε4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in men. Eur J Neurol 2011; 18:1046-52. [PMID: 21251163 DOI: 10.1111/j.1468-1331.2010.03330.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Several association studies have identified possible susceptibility factors for sporadic amyotrophic lateral sclerosis (SALS). Studies on the APOE gene provided conflicting results, especially about the effect on bulbar onset. We assessed the possible role of APOE gene in a large cohort of patients with ALS and matched controls. METHODS The APOE alleles were determined in 1482 patients with SALS and 955 controls and analysed by univariate and multivariate statistics, taking into account gender, site-of-onset and age-at-onset. RESULTS Patients with bulbar onset were more likely to be women [odds ratio (OR)=2.17; 95% CI: 1.74-2.72] and to be older (OR=3.47; 95% CI: 2.58-4.67). The ε4-carriers were more frequent in the bulbar-onset group than in the limb-onset group (OR=1.39 bulbar onset versus limb onset; 95% CI: 1.08-1.80) but this association was observed amongst men (OR=1.78; 95% CI: 1.25-2.53) and not women (OR=1.09; 95% CI: 0.75-1.59). CONCLUSION Our study provides evidence for a contribution of the ε4 allele in the occurrence of bulbar-onset ALS amongst men. We propose that men are normally protected by androgens against bulbar onset and that the ε4 allele inhibits this protection, perhaps by interfering with the androgen pathway.
Collapse
Affiliation(s)
- J Praline
- UMR INSERM U930, Université François-Rabelais, Tours Centre SLA, Service de Neurologie et Neurophysiologie Clinique, CHRU de Tours, Tours Cedex 2, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Collongues N, Marignier R, Zéphir H, Blanc F, Vukusic S, Outteryck O, Fleury M, Ruet A, Borgel F, Thouvenot E, Moreau T, Defer G, Derache N, Pelletier J, Audoin B, Debouverie M, Labauge P, Gout O, Camu W, Brassat D, Brochet B, Vermersch P, Confavreux C, Seze JD. High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Mult Scler 2011; 17:720-4. [DOI: 10.1177/1352458510396923] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background: Neuromyelitis optica (NMO) frequently begins with a monofocal episode of optic neuritis or myelitis. A concept named high-risk syndrome (HRS) for NMO has been proposed for patients with monofocal episodes and NMO-IgG antibodies. Objective: To describe HRS patients and compare them with NMO patients. Methods: We identified 30 patients with HRS: 18 with extensive myelitis (HRM) and 12 with optic neuritis (HRON), in a database pooling patients from 25 centres in France. Clinical, laboratory/magnetic resonance imaging (MRI) data and outcome were analysed and compared with a national cohort of 125 NMO patients extracted from the same database. Results: Mean follow-up was 4.8 years. Mean age at onset was 42.8 years (range: 12.4–70) with a female:male ratio of 0.9. Asymptomatic lesions were report on visual evoked potentials in 4/8 tested HRM patients and on spinal cord MRI in 2/7 HRON patients. Three patients died, two owing to a cervical lesion. HRS and NMO patients had similar clinical/paraclinical data, except for a predominance of men in the HRS group and a later mean age at onset in the HRM subgroup. Conclusion: The description of HRS patients is compatible with a monofocal form of NMO. Asymptomatic lesions could be included in a new set of NMO diagnostic criteria.
Collapse
Affiliation(s)
- N Collongues
- Strasbourg University Hospital, Strasbourg, France
| | | | - H Zéphir
- Lille University Hospital, Lille, France
| | - F Blanc
- Strasbourg University Hospital, Strasbourg, France
| | - S Vukusic
- Lyon University Hospital, Lyon, France
| | | | - M Fleury
- Strasbourg University Hospital, Strasbourg, France
| | - A Ruet
- Bordeaux University Hospital, Bordeaux, France
| | - F Borgel
- Grenoble University Hospital, Grenoble, France
| | - E Thouvenot
- Montpellier University Hospital, Montpellier, France
| | - T Moreau
- Dijon University Hospital, Dijon, France
| | - G Defer
- Caen University Hospital, Caen, France
| | - N Derache
- Caen University Hospital, Caen, France
| | - J Pelletier
- Marseille University Hospital, Marseille, France
| | - B Audoin
- Marseille University Hospital, Marseille, France
| | | | - P Labauge
- Nîmes University Hospital, Nîmes, France
| | - O Gout
- Rothschild Foundation Hospital, Paris, France
| | - W Camu
- Montpellier University Hospital, Montpellier, France
| | - D Brassat
- Toulouse University Hospital, Toulouse, France
| | - B Brochet
- Bordeaux University Hospital, Bordeaux, France
| | | | | | - J de Seze
- Strasbourg University Hospital, Strasbourg, France
| |
Collapse
|
27
|
Corcia P, Kabashi E, Lionnet C, Millecamps S, Danel V, Vandenberghe N, Pradat PF, Vourc’h P, Andres C, Lumbroso S, Rouleau G, Meininger V, Camu W. Phénotype des SLA avec mutation TDP-43 : Analyse d’une série française de 28 cas et revue de la littérature. Rev Neurol (Paris) 2011. [DOI: 10.1016/s0035-3787(11)70015-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Collongues N, Marignier R, Zéphir H, Papeix C, Fontaine B, Blanc F, Rodriguez D, Fleury M, Vukusic S, Pelletier J, Audoin B, Thouvenot E, Camu W, Barroso B, Ruet A, Brochet B, Vermersch P, Confavreux C, de Seze J. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010; 75:1084-8. [PMID: 20855851 DOI: 10.1212/wnl.0b013e3181f39a66] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years. Few data exist on patients with pediatric-onset NMO (p-NMO), with disease onset before age 18 years. We report the clinical and paraclinical features and long-term outcome of patients with p-NMO and compare them with a large adult-onset NMO (a-NMO) cohort. METHODS We performed a retrospective, multicenter study of patients with p-NMO in pediatric and adult medical centers. We identified 125 patients with NMO (12 p-NMO; 113 a-NMO) fulfilling the 2006 criteria. Data were collected using hospital files and standardized assessment forms for NMO. RESULTS Patients with p-NMO were followed up during a mean 19.3 years. Median age at onset was 14.5 years (4.1-17.9) with a female:male ratio of 3:1. Three patients (25%) fulfilled Paty criteria for multiple sclerosis on first brain MRI, including one patient with acute disseminated encephalomyelitis. Median interval between onset and residual Expanded Disability Status Scale (EDSS) score 4 was 20.7 years, score 6 was 26 years, and score 7 was 28.7 years. Median interval between onset and residual visual loss ≤1/10 was 1.3 years. Compared with a-NMO, p-NMO showed a longer time to EDSS scores 4 and 6, largely explained by the severity of the first myelitis in the a-NMO group. Time to first treatment was longer in the p-NMO group (13.1 vs 3.4 years). CONCLUSION Patients with p-NMO can present a diffuse inflammatory process on first brain MRI and have a longer time to disability than patients with a-NMO.
Collapse
Affiliation(s)
- N Collongues
- Department of Neurology, University Hospital of Strasbourg, 1, Place de l'Hôpital, 67091 Strasbourg, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Cohen M, Lebrun C, Aufauvre D, Chanalet S, Filleau-Bertogliatti C, Camu W, Thomas P, Malandain G, Clavelou P. [Longitudinal study of health related quality of life in multiple sclerosis: correlation with MRI parameters]. Rev Neurol (Paris) 2010; 166:894-900. [PMID: 20728910 DOI: 10.1016/j.neurol.2010.06.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2009] [Revised: 03/16/2010] [Accepted: 06/15/2010] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Health related quality of life (HRQOL) is often affected in multiple sclerosis (MS). Nevertheless, to our knowledge, there is no longitudinal study in the literature about the correlation between MRI parameters and HRQOL in MS patients. METHODS We included 28 patients with clinically definite relapsing remitting MS. All patients initiated subcutaneous interferon beta-1a therapy. To assess HRQOL, we used the SEP-59 scale, the French validated translation of MSQOL-54, and the MusiQoL scale. Conventional MRI was performed every year. Lesion load (LL) and brain atrophy were automatically measured using SepINRIA, a free software developed by INRIA in Sophia Antipolis. RESULTS The mean EDSS score was 1.7 and disease duration was 2.5 years. Our results revealed that HRQOL was significantly correlated to T1 and T2-LL with both SEP-59 and MusiQoL scales. T1-LL was better correlated with physical dimensions and T2-LL was better correlated with mental components. At 1-year follow-up, patients whose MRI showed either an increase of T1 LL or at least one gadolinium enhancing lesion had a worse HRQOL at the end of the study. Initial brain parenchymal fraction (BPF) measure was also correlated with the long-term follow-up HRQOL. EDSS scored at the end of the study had not significantly changed (1.3; P>0.05). CONCLUSION Our study revealed pertinent clinicoradiological correlations between HRQOL and MRI parameters in our cohort.
Collapse
Affiliation(s)
- M Cohen
- Service de neurologie, hôpital Pasteur, CHU de Nice, 30, voie Romaine, BP69, 06002 Nice cedex, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Millecamps S, Salachas F, Cazeneuve C, Gordon P, Bricka B, Camuzat A, Guillot-Noel L, Russaouen O, Bruneteau G, Pradat PF, Le Forestier N, Vandenberghe N, Danel-Brunaud V, Guy N, Thauvin-Robinet C, Lacomblez L, Couratier P, Hannequin D, Seilhean D, Le Ber I, Corcia P, Camu W, Brice A, Rouleau G, LeGuern E, Meininger V. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet 2010; 47:554-60. [DOI: 10.1136/jmg.2010.077180] [Citation(s) in RCA: 216] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C, Tchikviladzé M, Outteryck O, Vukusic S, Fleury M, Fontaine B, Brassat D, Clanet M, Milh M, Pelletier J, Audoin B, Ruet A, Lebrun-Frenay C, Thouvenot E, Camu W, Debouverie M, Créange A, Moreau T, Labauge P, Castelnovo G, Edan G, Le Page E, Defer G, Barroso B, Heinzlef O, Gout O, Rodriguez D, Wiertlewski S, Laplaud D, Borgel F, Tourniaire P, Grimaud J, Brochet B, Vermersch P, Confavreux C, de Seze J. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010; 74:736-42. [PMID: 20194912 DOI: 10.1212/wnl.0b013e3181d31e35] [Citation(s) in RCA: 158] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND There have been few epidemiologic studies on neuromyelitis optica (NMO) and none used the recent 2006 diagnostic criteria. Here we describe the clinical, laboratory, MRI, and disability course of NMO in a French cohort of 125 patients. METHODS We performed an observational, retrospective, multicenter study. Data were collected from September 2007 through August 2008, corresponding to the endpoint of the study. We identified 125 patients fulfilling the 2006 NMO criteria. Selection was made using hospital files and a specific clinical questionnaire for NMO. RESULTS Mean age at onset was 34.5 years (range 4-66) with a mean disease duration of 10 +/- 7.8 years at the endpoint. The patients were mainly (87%) Caucasian, with a female:male ratio of 3:1. In 90% of cases, the association of optic neuritis, longitudinal extensive myelitis, and a Paty-negative initial brain MRI was sufficient to fulfill the supportive criteria. Eighty-eight percent of patients were treated with immunosuppressive therapies. Median delay from onset to Expanded Disability Status Scale (EDSS) score 4 was 7 years; score 6, 10 years; and score 7, 21 years. The first episode of myelitis was immediately followed by an EDSS score > or = 4 in 37.3% of cases, and a severe residual visual loss was observed in 22% of patients after the first episode of optic neuritis. Multivariate analysis did not reveal any predictors of a poor evolution other than a high number of MRI brain lesions at diagnosis, which were predictive of a residual visual acuity < or = 1/10. CONCLUSIONS Our demographic data provide new data on disability in patients with neuromyelitis optica, most of whom were receiving treatment.
Collapse
Affiliation(s)
- N Collongues
- Department of Neurology, University Hospital of Strasbourg, 67091 Strasbourg, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Kluger N, Thouvenot E, Camu W, Guillot B. Cutaneous adverse events related to glatiramer acetate injection (copolymer-1, Copaxone®). J Eur Acad Dermatol Venereol 2009; 23:1332-3. [DOI: 10.1111/j.1468-3083.2009.03165.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
Belzil VV, Valdmanis PN, Dion PA, Daoud H, Kabashi E, Noreau A, Gauthier J, Hince P, Desjarlais A, Bouchard JP, Lacomblez L, Salachas F, Pradat PF, Camu W, Meininger V, Dupré N, Rouleau GA. Mutations in FUS cause FALS and SALS in French and French Canadian populations. Neurology 2009; 73:1176-9. [PMID: 19741216 DOI: 10.1212/wnl.0b013e3181bbfeef] [Citation(s) in RCA: 104] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND The identification of mutations in the TARDBP and more recently the identification of mutations in the FUS gene as the cause of amyotrophic lateral sclerosis (ALS) is providing the field with new insight about the mechanisms involved in this severe neurodegenerative disease. METHODS To extend these recent genetic reports, we screened the entire gene in a cohort of 200 patients with ALS. An additional 285 patients with sporadic ALS were screened for variants in exon 15 for which mutations were previously reported. RESULTS In total, 3 different mutations were identified in 4 different patients, including 1 3-bp deletion in exon 3 of a patient with sporadic ALS and 2 missense mutations in exon 15 of 1 patient with familial ALS and 2 patients with sporadic ALS. CONCLUSIONS Our study identified sporadic patients with mutations in the FUS gene. The accumulation and description of different genes and mutations helps to develop a more comprehensive picture of the genetic events underlying amyotrophic lateral sclerosis.
Collapse
Affiliation(s)
- V V Belzil
- CHUM Research Centre, Notre-Dame Hospital, Y-3633 Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Le Ber I, Camuzat A, Berger E, Hannequin D, Laquerrière A, Golfier V, Seilhean D, Viennet G, Couratier P, Verpillat P, Heath S, Camu W, Martinaud O, Lacomblez L, Vercelletto M, Salachas F, Sellal F, Didic M, Thomas-Anterion C, Puel M, Michel BF, Besse C, Duyckaerts C, Meininger V, Campion D, Dubois B, Brice A. Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology 2009; 72:1669-76. [PMID: 19433740 DOI: 10.1212/wnl.0b013e3181a55f1c] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- I Le Ber
- CRicm-UMRS975 (formerly INSERM, UMR_S679), France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Meininger V, Antoine JC, Arne-Bes M, Broussolle E, Bruneteau G, Camdessanche J, Camu W, Carluer L, Cintas P, Clavelou P, Corcia P, Couratier P, Danel-Brunaud V, Desnuelle C, Destée A, Dib M, Fleury MC, Furby A, Giroud M, Gonzales J, Guy N, Kolev I, Lacomblez L, Lardillier-Noel D, Le Forestier N, Maugin D, Nicolas G, Pittion S, Pouget J, Pradat P, Rousso E, Salachas F, Soriani M, Tranchant C, Vandenberghe N, Verschueren A, Viader F, Vial C. Les méfaits d’Internet dans les traitements de la sclérose latérale amyotrophique. Rev Neurol (Paris) 2009; 165:207-10. [DOI: 10.1016/j.neurol.2009.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Carlander B, Vincent T, Le Floch A, Pageot N, Camu W, Dauvilliers Y. Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes. BMJ Case Rep 2009; 2009:bcr08.2008.0709. [PMID: 21686670 DOI: 10.1136/bcr.08.2008.0709] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Devic's neuromyelitis optica (NMO) is a severe demyelinating disease of the central nervous system, often misdiagnosed as multiple sclerosis, and involving mainly optic nerves and the spinal cord. We report on a peculiar case of relapsing NMO with severe recurrent dysautonomia and hypersomnia, in which we had the opportunity to observe a dramatic decrease in hypocretin/orexin cerebrospinal fluid level.
Collapse
Affiliation(s)
- B Carlander
- Department of Neurology, Hôpital Gui-de-Chauliac, Montpellier, France
| | | | | | | | | | | |
Collapse
|
37
|
Gil J, Funalot B, Verschueren A, Danel-Brunaud V, Camu W, Vandenberghe N, Desnuelle C, Guy N, Camdessanche JP, Cintas P, Carluer L, Pittion S, Nicolas G, Corcia P, Fleury MC, Maugras C, Besson G, Le Masson G, Couratier P. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol 2009; 15:1245-51. [PMID: 18973614 DOI: 10.1111/j.1468-1331.2008.02307.x] [Citation(s) in RCA: 109] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND AND PURPOSE To prospectively investigate causes of death and the circumstances surrounding death in 302 patients with amyotrophic lateral sclerosis (ALS). The functional status of patients immediately before death was also determined. METHODS Information was obtained from neurologists at ALS centres, patients' files, and, when deaths occurred outside a medical facility, attending physicians. RESULTS Most patients (63%) died in a medical facility. The most frequently reported cause of death was respiratory failure (77%), including terminal respiratory insufficiency (58%), pneumonia (14%), asphyxia due to a foreign body (3%) and pulmonary embolism (2%). Ten per cent of patients died from other causes: post-surgical or traumatic conditions (5%), cardiac causes (3.4%), suicide (1.3%) and sudden death of unknown origin (0.7%). The cause of death could not be determined in 13% of cases (6% inside a medical facility and 25% outside). At the time of death, only 55% of patients were receiving riluzole, 33% were undergoing non-invasive ventilation, 3% had a tracheotomy and 37% a gastrostomy. CONCLUSION The information provided by this study helps to improve our understanding of the natural history of the disease and may help optimize the quality of care we can offer patients at the end of life.
Collapse
Affiliation(s)
- J Gil
- EA 3174 Faculté de Médecine, Limoges, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Tchikviladzé M, Ritleng C, Outteryck O, Vukusic S, Fleury M, Mignot C, Brassat D, Clanet M, Milh M, Ruet A, Lebrun-Frenay C, Camu W, Debouverie M, Créange A, Moreau T, Labauge P, Castelnovo G, Edan G, Lepage E, Defer G, Barroso B, Thouvenot E, Heinzlef O, Gout O, Rodriguez D, Augustin J, Wiertlewski S, Laplaud D, Borgel F, Slassi I, Berroir S, Tourniaire P, Grimaud J, Brochet B, Vermersch P, Confavreux C, de Sèze J. Neuromyélite optique de Devic et patients à haut risqué : enquête rétrospective nationale. Rev Neurol (Paris) 2009. [DOI: 10.1016/s0035-3787(09)70025-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
39
|
Daoud H, Valdmanis PN, Kabashi E, Dion P, Dupré N, Camu W, Meininger V, Rouleau GA. Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J Med Genet 2008; 46:112-4. [PMID: 18931000 DOI: 10.1136/jmg.2008.062463] [Citation(s) in RCA: 140] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
AIMS AND BACKGROUND Mutations in the TARDBP gene, which encodes the TAR DNA binding protein (TDP-43), have been described in individuals with familial and sporadic amyotrophic lateral sclerosis (ALS). We screened the TARDBP gene in 285 French sporadic ALS patients to assess the frequency of TARDBP mutations in ALS. RESULTS Six individuals had potentially deleterious mutations of which three were novel including a Y374X truncating mutation and P363A and A382P missense mutations. This suggests that TARDBP mutations may predispose to ALS in approximately 2% of the individuals followed in this study. CONCLUSION Our findings, combined with those from other collections, brings the total number of mutations in unrelated ALS patients to 17, further suggesting that mutations in the TARDBP gene have an important role in the pathogenesis of ALS.
Collapse
Affiliation(s)
- H Daoud
- Centre of Excellence in Neuromics, CHUM Research Center and the Department of Medicine, University of Montreal, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Gabelle A, Vallat JM, Flageul B, Andre P, Camu W. [Sensory-motor neuropathy: a slow and misleading case of leprosy]. Rev Neurol (Paris) 2008; 164:964-8. [PMID: 18808760 DOI: 10.1016/j.neurol.2007.11.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2007] [Revised: 09/04/2007] [Accepted: 11/27/2007] [Indexed: 11/19/2022]
Abstract
The diagnostic process of sensory-motor neuropathies is difficult. Atypical variants and rare etiologies also contribute to delay the diagnosis. We report the case of a 70-year-old woman with slowly progressive asymmetric axonal sensory-motor neuropathy. Leprosy was identified after an eight-year delay. Nerve biopsy was required to establish the diagnosis: electron microscopy revealed debris of Hansen's bacillus in the nerve. Treatment was fully curative after several months. Leprosy is a rare cause of neuropathy in Europeans. Systematic inquiry about travel to endemic areas would be helpful in establishing the diagnosis. In such cases, nerve biopsy is crucial.
Collapse
Affiliation(s)
- A Gabelle
- Service de neurologie-explorations, CHU Gui-de-Chauliac, 80, avenue Augustin-Fliche, 34285 Montpellier cedex 05, France
| | | | | | | | | |
Collapse
|
41
|
Valdmanis PN, Kabashi E, Dyck A, Hince P, Lee J, Dion P, D'Amour M, Souchon F, Bouchard JP, Salachas F, Meininger V, Andersen PM, Camu W, Dupre N, Rouleau GA. Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. Neurology 2008; 71:514-20. [DOI: 10.1212/01.wnl.0000324997.21272.0c] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
42
|
Carlander B, Vincent T, Le Floch A, Pageot N, Camu W, Dauvilliers Y. Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes. J Neurol Neurosurg Psychiatry 2008; 79:333-4. [PMID: 18281452 DOI: 10.1136/jnnp.2007.135228] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Gonzalez A, Juntas Morales R, Pageot N, Charif M, Alphandery A, Camu W. Hyperactivité et hypoxie dans la SLA. Rev Neurol (Paris) 2008. [DOI: 10.1016/s0035-3787(08)70032-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Thouvenot E, Hillaire-Buys D, Bos-Thompson MA, Rigau V, Durand L, Guillot B, Camu W. Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. Mult Scler 2007; 13:941-4. [PMID: 17881403 DOI: 10.1177/1352458507076385] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Glatiramer acetate (GA), a well tolerated immunomodulatory treatment for relapsing—remitting multiple sclerosis (RR-MS), consists of a 4-amino acid polymer that mimics the myelin basic protein (MBP). We report the first case of biopsy-proven erythema nodosum (EN) in a patient presenting RR-MS under GA treatment. Comprehensive exams were negative in the search of the etiology of EN, which spontaneously resolved despite treatment continuation. GA treatment is known to generate reactive polyclonal antibodies that can cross-react with myelin epitopes, like MBP. These antibodies may also be implicated in allergenic reactions and auto-immune adverse events, such as anaphylactic shock, lymphadenopathy, livedo-like dermatitis, or lymphocytic infiltration. EN is an unspecific skin reaction occurring in several disorders and induced by many treatments. As EN can result from a polyclonal antibody response or type I hypersensitivity mechanisms, we hypothesize that GA treatment could be responsible for the occurrence of EN. Multiple Sclerosis 2007; 13: 941—944. http://msj.sagepub.com
Collapse
Affiliation(s)
- E Thouvenot
- Service de Neurologie, Hôpital Gui de Chauliac 80 avenue Augustin Fliche, 34295, Montpellier Cedex 5, France
| | | | | | | | | | | | | |
Collapse
|
45
|
Fourcade G, Morales R, Pageot N, Timmerman V, Camu W. J - 11 Une nouvelle famille d’HMN distale liée à une mutation du gène HSP27. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90663-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
46
|
Camu W. Les SLA familiales sont-elles cliniquement différentes ? Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90998-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
47
|
Corcia P, Camu W, Halimi JM, Vourc'h P, Antar C, Vedrine S, Giraudeau B, de Toffol B, Andres CR. SMN1 gene, but not SMN2, is a risk factor for sporadic ALS. Neurology 2006; 67:1147-50. [PMID: 16931506 DOI: 10.1212/01.wnl.0000233830.85206.1e] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND SMN1 gene deletions cause spinal muscular atrophy, and SMN2 gene deletions have been associated with sporadic lower motor neuron diseases. OBJECTIVES To study the frequency of abnormal SMN1 gene copy numbers and to determine whether SMN2 gene modulates the risk of amyotrophic lateral sclerosis (ALS) or the duration of evolution. METHOD The authors studied SMN1 and SMN2 genes in 600 patients with sporadic ALS and 621 controls using a quantitative PCR method. RESULTS The authors found an association of ALS with an abnormal copy number (one or three copies) of SMN1 gene (p < 0.0001) with an OR of 2.8 (1.8 to 4.4, 95% CI). There was no association with SMN2 copy numbers and no effect of SMN2 copies on the duration of evolution in ALS independently of SMN1 copy number. CONCLUSION Abnormal SMN1 gene copy numbers are a genetic risk factor in sporadic amyotrophic lateral sclerosis. There was no modulator effect of the SMN2 gene.
Collapse
Affiliation(s)
- P Corcia
- INSERM U619, Faculté de Médecine, Tours, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Roy-Bellina S, Camu W. [Psychological treatment for the patient and caregivers during the course of amyotrophic lateral sclerosis]. Rev Neurol (Paris) 2006; 162 Spec No 2:4S295-4S300. [PMID: 17128129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Amyotrophic lateral sclerosis is a devastating disorder for which the psychological consequences of both the diagnosis announcement and the evolution of paralysis not only concern the patient but also his family. The role of the psychologist is to develop an individualized follow up considering the patient in his globality. The first consultation is, ideally, initiated after a medical consultation explaining the importance of the psychological area in ALS patient care. The psychological follow up will consist in an empathic listening of history and problems. Information will also be given to the patient by the psychologist who's role should not be only passive. When talking about "globality" of the psychological intervention for a given patient, his family takes a determinant place. The psychologist should be able to establish a contact with the family members concerned by the daily support to the patient. The psychological processes through which a patient will evolve should be explained to the family. Depression frequently affects family members, and a specific follow up in those cases has to be undertaken as soon as possible. Such a depressive reaction may also take place after death and a psychological follow up do not end after the death of a patient. The role of a psychologist in ALS care ideally takes places in the context of a multidisciplinary team such as a motoneuron clinic now largely available in our country. The burden of care is frequently heavy both for the family and the team of professional carers into and outside the hospital. The psychologist has a role of mediation between those persons, facilitating verbal exchanges, paying attention to specific difficulties and maintaining a fruitful exchange between the carers, the patient and his family. More prospectively, the psychologist also has a pedagogic role for the carers explaining psychological processes and giving clues for a constructive relationship between the patient and his family and also between this patient and his carers.
Collapse
Affiliation(s)
- S Roy-Bellina
- Clinique du Motoneurone, Service d'Explorations Neurologiques, Hôpital Gui-de-Chauliac, Montpellier
| | | |
Collapse
|
49
|
Camu W. Quelle est la place de l’enquête génétique ? Rev Neurol (Paris) 2006. [DOI: 10.1016/s0035-3787(06)75169-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Camu W. [What is the role of the genetic survey in amyotrophic lateral sclerosis?]. Rev Neurol (Paris) 2006; 162 Spec No 2:4S91-4S95. [PMID: 17128094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
The genetic inquiry in the diagnostic process of amyotrophic lateral sclerosis (ALS) need to be precise and systematic. Several hereditary neurologic disorders may initially mimic ALS, such as dominant spino-cerebellar ataxia or spastic paraplegia. Other hereditary motor neuron disorders are clinically more difficult to distinct from ALS such as Kennedy's disease, adult-onset spinal muscular atrophies or juvenile ALS. When a final diagnostic of ALS is established, the genetic inquiry aims at identifying a familial ALS (FALS) case. Almost 10 to 20 percent of ALS cases are familial. It is now admitted that 10 to 20 percent of those cases are due to SOD1 gene mutations. Such mutations may have a dominant or recessive inheritance. They are mainly found in multigenerational families. In 80 percent of the FALS cases, only two ALS cases are found in the pedigree. One cannot know whether this represent dominant cases with low penetrance, recessive inheritance or a multigenic, hereditary complex, disorder. More other, not all the SOD1 mutations have been demonstrated as causal. These elements are strong enough to suggest to precisely study, in the presence of a given SOD1 mutation, both the clinical phenotype, the data from the literature and, as often as possible, the segregation of the mutation into the family, before ascertaining that the mutation is responsible for a hereditary case of ALS. In every case, the genetic inquiry together with its conclusions should be done with caution, taking into account both the patient's need of a clear information and his anxiety regarding his descent.
Collapse
Affiliation(s)
- W Camu
- Clinique du Motoneurone, Service d'Explorations Neurologiques, Hôpital Gui-de-Chauliac, Montpellier, France.
| |
Collapse
|